MAZE - NASDAQ
Maze Therapeutics, Inc.
$25.06
+3.2%Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
At a Glance
Live SnapshotMaze Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Maze Therapeutics, Inc. Cash Flow Statement
MAZE • NASDAQ
| Maze Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-131.1M | 52.2M | -100.4M | -114.9M | |
2.4M | 3.3M | 4.1M | 3.8M | |
16.4M | 9.6M | 8.7M | 6.7M | |
2.7M | 12.3M | 7.1M | 8.4M | |
(0.0) | (1.2M) | (0.0) | (0.0) | |
-2.3M | -1.5M | -6.3M | -3.2M | |
-111.9M | 76M | -86.8M | -99.2M | |
INVESTING ACTIVITIES | ||||
-794K | -1.1M | -441K | -2M | |
(0.0) | (0.0) | (0.0) | -1.2M | |
-187.7M | (0.0) | (0.0) | (0.0) | |
17.5M | 0.0 | 0.0 | 0.0 | |
-171M | -1.1M | -441K | -3.2M | |
FINANCING ACTIVITIES | ||||
275.8M | 68.4M | 209K | 1.7M | |
0.0 | 24.5M | 16.2M | 0.0 | |
-500K | 0.0 | 0.0 | 0.0 | |
275.3M | 92.8M | 16.4M | 1.7M | |
CASH FLOW SUMMARY | ||||
-7.6M | 167.7M | -70.9M | -100.6M | |
197.9M | 30.2M | 101.1M | 201.8M | |
190.3M | 197.9M | 30.2M | 101.1M | |
-112.7M | 74.8M | -87.3M | -101.2M |
SEC Filings
MAZE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 04, 2026 | February 02, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your MAZE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.